EBV Clinical Trials

21 clinical trials for EBV across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection — RECRUITING · PHASE1
• The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise — RECRUITING
• Golidocitinib Combined With Selinexor for CAEBVD — RECRUITING · PHASE2
• A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System® — RECRUITING · PHASE2
• Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults — COMPLETED · PHASE1
• Comparison of Technics for Determination of Epstein-Barr Virus Serological Diagnosis — COMPLETED
• mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults — NOT_YET_RECRUITING · PHASE1
• Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) — COMPLETED · PHASE1
• KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial — NOT_YET_RECRUITING · PHASE1
• A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT — OTHER · NA
• Belatacept 3 Month Post Transplant Conversion Study — COMPLETED · PHASE4
• Response Prediction in EBV-HLH Using Metabonomics Analysis — OTHER
• PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. — COMPLETED · PHASE2
• CNTRP POSITIVE Study — COMPLETED
• Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial — TERMINATED · PHASE2
• Cytotoxic T Cells to Prevent Virus Infections — COMPLETED · PHASE1
• Plasma EBV DNA Monitoring in Post-treatment NPC Patients — COMPLETED
• Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma — TERMINATED · PHASE2
• Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation — OTHER · PHASE2
• Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation — OTHER · PHASE1
• Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors — TERMINATED · PHASE1

Refine this search